- 1 Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National
- 2 Clinical Research Network: Results from PCORnet<sup>®</sup>
- 3 Short Title: Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness
- 4 Jason P. Block, MD, MPH<sup>1</sup>, Keith A. Marsolo, PhD<sup>2</sup>, Kshema Nagavedu, MPH<sup>1</sup>, L. Charles
- 5 Bailey, MD, PhD<sup>3</sup>, Henry Cruz, BA<sup>4</sup>, Christopher B. Forrest, MD, PhD<sup>3</sup>, Kevin Haynes,
- 6 PharmD, MSCE<sup>5</sup>, Adrian F. Hernandez, MD, MHS<sup>6</sup>, Rainu Kaushal, MD, MPH<sup>7</sup>, Abel Kho,
- 7 MD<sup>8</sup>, Kathleen M. McTigue, MD, MPH, MS<sup>9</sup>, Vinit P. Nair, BPharm, MS<sup>10</sup>, Richard Platt, MD,
- 8 MSc<sup>1</sup>, Jon Puro, MPA/HA<sup>11</sup>, Russell L. Rothman, MD, MPP<sup>12</sup>, Elizabeth Shenkman, PhD<sup>13</sup>,
- 9 Lemuel Russell Waitman, PhD<sup>14</sup>, Mark G. Weiner, MD<sup>7</sup>, Neely Williams, EdD<sup>15</sup>, Thomas W.
- 10 Carton, PhD, MS<sup>16</sup> on behalf of PCORnet<sup>®</sup> Network Partners\*
- <sup>1</sup>Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical
- 12 School, Boston, Massachusetts; <sup>2</sup>Department of Population Health Sciences, Duke University,
- 13 Durham, North Carolina; <sup>3</sup>Applied Clinical Research Center, Department of Pediatrics,
- 14 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; <sup>4</sup> PCORnet<sup>®</sup>, National Patient-
- <sup>15</sup> Centered Clinical Research Network, Washington, D.C.; <sup>5</sup>HealthCore, Wilmington, Delaware;
- <sup>6</sup>Duke Clinical Research Institute, Durham, North Carolina; <sup>7</sup>Department of Population Health
- 17 Sciences Weill Cornell Medicine, New York, New York; <sup>8</sup>Center for Health Information
- 18 Partnerships, Northwestern University, Chicago, Illinois; <sup>9</sup>Department of Medicine, University
- 19 of Pittsburgh, Pittsburgh, Pennsylvania; <sup>10</sup>PRACnet, Sharon, MA; <sup>11</sup>OCHIN, Inc., Portland, OR;
- <sup>12</sup>Center for Health Services Research, Vanderbilt University Medical Center, Nashville,
- 21 Tennessee; <sup>13</sup>Health Outcomes & Biomedical Informatics, College of Medicine, University
- of Florida, Gainesville, Florida; <sup>14</sup>Department of Internal Medicine, University of Kansas
- 23 Medical Center, Kansas City, Kansas; <sup>15</sup>Community Partners Network Inc, Nashville, Tennessee;
- 24 <sup>16</sup>Louisiana Public Health Institute, New Orleans, LA
- 25
- 26
- 27 \*Collaborative authors are listed in an Appendix
- 28
- Address correspondence to: Jason Block, MD, MPH, Division of Chronic Disease Research
- 30 Across the Lifecourse, Department of Population Medicine, Harvard Pilgrim Health Care
- Institute, Harvard Medical School, 401 Park Drive, Boston, MA 02215, 617-867-4841,
- 32 jblock1@partners.org
- 33
- 34
- 35 Abbreviations: EHR electronic health record, CDM Common Data Model, ETL extract-
- transfer-load procedure to move data from a clinical data warehouse to the PCORnet Common
- 37Data Model, HTN hypertension, Diabetes Type 2 Diabetes Mellitus, Pulm pulmonary
- disease, CKD chronic kidney disease, CAD coronary artery disease, CHF congestive heart
- 39 failure, Coag Coagulopathy, Cancer Cancer other than non-melanoma skin cancer,

- 40 Immunosupp use of immunosuppressive medications; Any any care setting, Amb –
- 41 ambulatory care setting, IP/ED inpatient or emergency department, Vent inpatient or
- 42 emergency department with procedure codes indicating use of mechanical ventilation, PNA -
- 43 pneumonia

- 45 Manuscript Word Count: 3909
- 46 Abstract Word Count: 313

#### 47 Abstract

- 49 Background: National data from diverse institutions across the United States are critical for
- 50 guiding policymakers as well as clinical and public health leaders. This study characterized a
- 51 large national cohort of patients diagnosed with COVID-19 in the U.S., compared to patients
- 52 diagnosed with viral pneumonia and influenza.
- 53 **Methods and Findings:** We captured cross-sectional information from 36 large healthcare
- 54 systems in 29 U.S. states, participating in PCORnet<sup>®</sup>, the National Patient-Centered Clinical
- 55 Research Network. Patients included were those diagnosed with COVID-19, viral pneumonia
- and influenza in any care setting, starting from January 1, 2020. Using distributed queries
- 57 executed at each participating institution, we acquired information for patients on care setting
- 58 (any, ambulatory, inpatient or emergency department, mechanical ventilator), age, sex, race,
- 59 state, comorbidities (assessed with diagnostic codes), and medications used for treatment of
- 60 COVID-19 (hydroxychloroquine with or without azithromycin; corticosteroids, anti-interleukin-
- 61 6 agents).
- During this time period, 24,516 patients were diagnosed with COVID-19, with 42% in an
- 63 emergency department or inpatient hospital setting; 79,639 were diagnosed with viral pneumonia
- 64 (53% inpatient/ED) and 163,984 with influenza (41% inpatient/ED). Among COVID-19
- patients, 68% were 20 to <65 years of age, with more of the hospitalized/ED patients in older age
- ranges (23% 65+ years vs. 12% for COVID-19 patients in the ambulatory setting). Patients with
- viral pneumonia were of a similar age, and patients with influenza were much younger.
- 68 Comorbidities were common, especially for patients with COVID-19 and viral pneumonia, with
- 69 hypertension (32% for COVID-19 and 46% for viral pneumonia), arrhythmias (20% and 35%),
- and pulmonary disease (19% and 40%) the most common. Hydroxychloroquine was used in
- treatment for 33% and tocilizumab for 11% of COVID-19 patients on mechanical ventilators
- 72 (25% received azithromycin as well).
- 73 Conclusion and Relevance: PCORnet leverages existing data to capture information on one of
- the largest U.S. cohorts to date of patients diagnosed with COVID-19 compared to patients
- 75 diagnosed with viral pneumonia and influenza.

76 The novel coronavirus SARS-CoV-2 has resulted in unprecedented challenges to the global 77 medical and public health sectors. The virus has spread rapidly across the world, leading policymakers, clinicians, first responders, and public health professionals to coordinate responses 78 79 with limited information about effects on diverse populations and potential treatments. Over the first few months of the pandemic, data on patients with COVID-19 came from varied sources, 80 81 often as single-institution or regional case series or through case reports to public health 82 authorities, typically based on positive lab tests (1-5). Case reports to public health authorities and popular dashboards that rely on this information often lack detailed information about 83 84 patient characteristics, use of treatments, or course of illness (2, 6-9). 85 A rapidly evolving pandemic presents tremendous uncertainty. The pattern of disease is typically 86 unknown initially, and knowledge can flow in asymmetric ways, often driven by anecdotes, press 87 reports, and social media. Throughout much of the COVID-19 pandemic, testing has been 88 insufficient, limiting knowledge about the scope of the pandemic and characteristics of patients 89 90 infected. Treatments have become mainstays before being fully vetted (10-12). 91 Leaders, institutions, researchers, and patients need extensive and accurate information about 92 93 characteristics of patients infected, utilization of treatments and disease course, ideally from diverse settings across large geographic regions. Research networks that can capture this 94 95 information across many healthcare systems have an important role during a pandemic response, especially because they can provide more generalizable, real-world information on a diverse 96 population. In this article, we describe characteristics of one of the largest national cohorts of 97 98 patients to date diagnosed with COVID-19 and compare this cohort to patients diagnosed with

99 other viral illnesses in institutions participating in PCORnet<sup>®</sup>, the National Patient-Centered
100 Clinical Research Network.

101

#### 102 Methods

103 Developed with funding by the Patient-Centered Outcomes Research Institute<sup>®</sup> (PCORI<sup>®</sup>),

104 PCORnet<sup>®</sup> is a network-of-networks developed to facilitate comparative effectiveness research

using electronic health record (EHR) and other healthcare data (13, 14). The Network currently

has participation from 251 medical institutions, 337 hospitals, 3,574 primary care practices, and

107 1,024 community clinics embedded within nine Clinical Research Networks (i.e., consortia of

108 health systems called PCORnet Network Partners) and 61 data contributing sites (i.e., individual

109 health systems); the Network also has participation from two Health Plan Research Networks.

110 PCORnet Network Partners (NPs) are well suited to develop and analyze cohorts of patients

across many of the largest health systems in the United States. While set up to accommodate

112 comparative effectiveness and epidemiologic research, the network has features that allow for a

transition to rapid querying of data in a medical and public health crisis. In this study on COVID-

114 19 patients, 37 of the 61 data contributing sites participated.

115

116 PCORnet Common Data Model

117 PCORnet operates as a distributed research network, where data are held locally behind

institutional firewalls, with queries sent to institutions from a central PCORnet Coordinating

119 Center and results returned in the form of aggregate counts or summary statistics. NPs also have

120 the capacity to generate patient-level data and to link electronic health records to claims data for

121 specific projects. The NPs utilize the PCORnet Common Data Model, in which each data

122	contributing site maps its clinical and/or administrative claims data into a standardized
123	representation (15). The most recent version of the PCORnet Common Data Model, v5.1,
124	provides standards for information on demographics, diagnoses, vital signs, laboratories,
125	prescriptions and dispensed medications, medications administered (multiple settings),
126	procedures, and facility and patient geographic information, among other information (15).
127	These data are normally updated quarterly by sites, and the PCORnet Coordinating Center
128	curates the data to ensure conformance with the Common Data Model, data plausibility, and data
129	completeness (16). The Coordinating Center provides metrics based on these data quality
130	domains to sites, allowing them to troubleshoot any data problems; some deficiencies require
131	mitigation before the site can participate in PCORnet queries.
132	
133	Prompted by the COVID-19 pandemic, PCORnet NPs agreed to abruptly change the operation of
134	the network, allowing for rapid capture of information on patients infected with COVID-19. To
135	facilitate this, starting in early April, NPs began updating their data weekly instead of quarterly.
136	Rather than doing this for all patients (which can involve millions of patients and require
137	considerable time), PCORnet sites focused the refresh on patients that had at least one
138	International Classification of Diseases, 10 <sup>th</sup> revision, Clinical Modification (ICD-10-CM)
139	diagnostic code for a respiratory illness or had a lab order for a SARS-CoV-2 test recorded
140	beginning January 1, 2020 (Fig 1) (17). This respiratory illness filter created a COVID-19-
141	focused Common Data Model that included all information available in the typical "full
142	population" Common Data Model but for many fewer patients. The Common Data Model
143	respiratory illness filter included ICD-10-CM codes for coronavirus (COVID-19 and other),
144	pneumonia, bronchitis, influenza, upper respiratory infections, fever, cough, respiratory failure or

- acute respiratory distress syndrome, and shortness of breath (S Methods Note). The codes for
- 146 SARS-CoV-2 laboratory orders were Special Use terms identified via the Logical Observation
- 147 Identifiers Names and Codes (LOINC) Prerelease Page, as well as guidance from the Centers for
- 148 Medicare and Medicaid Services (CMS) on SARS-CoV-2-related Healthcare Common
- 149 Procedure Coding System (HCPCS) codes (18). Sites first began populating their COVID-19
- 150 Common Data Model during the week of March 27<sup>th</sup>. The timeline for implementation varied by
- site based on ability to change data infrastructure and alter governance to allow for frequent
- 152 updates and queries.
- 153

## Fig 1. PCORnet Common Data Models, including standard and COVID-19 Common Data Model.

The PCORnet Common Data Model includes information collected through various clinical data 156 systems, including electronic health records (EHR) and health insurance claims or pharmacy 157 dispensing records. Once data are entered by the user, systems transfer data to a data warehouse 158 that is unique to their own health system and system vendor (e.g., Epic, Cerner). The typical 159 process for populating the PCORnet Common Data Model is through an extraction-transfer-160 161 loading (ETL) procedure that allows for transformation of raw information into a form that is compliant with the Common Data Model specifications. This transformation allows for 162 consistency across health systems and centralized querying of data, and the PCORnet ETL and 163 Common Data Model data refresh occurs quarterly. The PCORnet COVID-19 Common Data 164 Model utilizes a similar process but rather than including information on all patients, it includes 165 information only on patients who have had at least one respiratory illness diagnostic code or a 166 lab test ordered for SARS-CoV-2 since January 1, 2020. This process occurs weekly and 167 includes data with a lag time between 1 day to 7 days, depending on the site. 168

169

#### 170 *Query Development Process and Cohort Characterization*

- 171 The PCORnet Coordinating Center has developed standardized statistical programs, called
- 172 modular programs, that can capture aggregate descriptive information on defined cohorts. These
- 173 programs define a cohort or multiple cohorts and then capture broad descriptive information,
- including demographics, comorbidities (and symptoms based on billing codes), prescriptions or
- 175 hospital-administered medications, presence of laboratory results, and geographic information.

NPs return data as counts and frequencies for variables specified; the PCORnet Coordinating
Center combines results across NPs, producing a summary report of Network-wide aggregate
results. Submission and use of these aggregate data are covered by a Network-wide Data
Security Agreement.

180

Starting from the broader group of patients whose information was in the COVID-19 Common 181 182 Data Model, we defined a cohort of patients with ICD-10-CM diagnostic codes for COVID-19 or other coronaviruses (our case definition for COVID-19 for this study), viral pneumonia, or 183 influenza (S1 Table). The case definition did not use laboratory data. We assessed patients with 184 these three infections to enable some characterization of patients with other infections relevant to 185 COVID-19 as comparison cohorts. The viral pneumonia and influenza cohorts excluded patients 186 187 who had COVID-19 (or other coronavirus) ICD-10-CM codes. We stratified our cohort based on these three infections as well as the setting of diagnosis: 1) any setting, 2) ambulatory, 3) 188 189 inpatient or emergency department, or 4) inpatient or emergency department with procedure 190 codes identifying use of mechanical ventilation. Patients could be included in multiple care settings, if patients received diagnostic codes in more than one. We identified mechanical 191 ventilation usage through ICD-10-CM, HCPCS and Current Procedural Terminology (CPT) 192 193 codes. All codes for case definitions, comorbidities, treatments and labs were posted on GitHub (https://github.com/PCORnet-DRN-OC/Query-194

195 <u>Details/tree/master/COVID\_weekly\_query/2020\_04\_29</u>).

196

197 *Comorbidities, Treatments and Symptoms* 

198	We captured aggregate data across NPs for demographic characteristics of patients, including
199	age group, sex, and race, using value sets defined in the PCORnet Common Data Model v5.1.
200	Sex categories allowed for Male, Female, and Other. For race, several categories, including
201	Native Hawaiian/Other Pacific Islander and Alaskan Native/American Indian, were less common
202	and typically $<1\%$ for all cohorts.

203

We included a detailed assessment of comorbidities. We chose these based on discussions with 204 205 experts regarding the comorbidities that might affect outcomes with COVID-19, as well as 206 information presented in early publications regarding COVID-19 outcomes. Patients were 207 considered to have a disease/condition if they had at least one ICD-10-CM code for the disease/condition recorded any time over a three-year period prior to the date of their index 208 209 diagnosis. We required only one code to account for the possibility that some patients had their 210 first encounter with the healthcare system for their admission for COVID-19 and may only have 211 one code listed for a comorbidity. Using RxNorm and National Drug Codes (NDC) lists, we 212 identified use of immunosuppressive medications over the same three-year period (19, 20). 213 Similarly, we captured information on medications being used for treatment, with an assessment of prescriptions given in the 14-day period before and after the index diagnosis. These included 214 215 hydroxychloroquine and chloroquine, alone or in combination with azithromycin, as well as corticosteroids and anti-IL-6 agents (siltuximab, sarilumab, tocilizumab) used to treat the 216 217 cytokine storm that can occur with severe COVID-19. We also captured use of critical care 218 procedure/billing CPTs (99291, 99292) during this period and the presence of laboratory tests, 219 identified with LOINC codes, that are commonly used in the assessment of COVID-19. Lastly, 220 we categorized weight status for each cohort, using the most recent height and weight available,

221 up to one year prior to the index diagnosis date. We calculated measures separately by age group, 222 using body mass index (BMI) for adults and Centers for Disease Control and Prevention macros 223 for calculation of BMI z-scores and weight status for children < 20 years of age (21). 224 Results 225 The query captured aggregate data on 24,516 patients with a COVID-19 diagnosis from 36 data 226 227 contributing sites, across 29 states; 37 sites responded to the query, but 1 site had no cases 228 reported (S2 Table). Across the 36 sites, percent contributions to the overall COVID-19 229 population ranged from <1% to 14% with 11 sites each contributing  $\geq$  4%; these 11 sites included 70% of all COVID-19 patients. The most commonly represented states were Illinois 230 (18%), Wisconsin (11%), and Florida (9%), with 18% of patients missing geographic 231

information. Among patients diagnosed with COVID-19, 42% were diagnosed in an emergency

233 department or inpatient hospital setting, and the most commonly used codes for the diagnosis of

234 COVID-19 were B34.2 (19%), B97.29 (33%), and U07.1 (62%). A lab test for SARS-CoV-2

was present for 68% of patients diagnosed (S1 Figure). For comparison conditions, the query

identified 79,639 diagnosed with viral pneumonia (53% in hospital/ED) and 163,984 with

influenza (41% in hospital/ED). Labs commonly used in the assessment of patients with COVID-

238 19 were variably available in the PCORnet Common Data Model, with creatinine, alanine

aminotransferase and aspartate aminotransferase, and lymphocyte count the most common.

240

241 Most COVID-19 patients were diagnosed in March and April 2020 (25% and 53% respectively),

in contrast to viral pneumonia and influenza patients, who were most often diagnosed in January

and February (64% and 84% respectively). Only 0.4% of influenza cases were diagnosed in

244	April/May 2020 (Table 1). Among COVID-19 patients, 68% were 20 to <65 years of age, with
245	more of the hospitalized/ED patients in older age ranges (23% 65+ years compared to 12% for
246	COVID-19 patients in the ambulatory setting) (Table 1). Patients with influenza were younger
247	than patients with COVID-19 or viral pneumonia (63% hospitalized/ED with influenza were <20
248	years of age compared to 16% for COVID-19 and 21% for viral pneumonia). More female
249	patients (55%) received a COVID-19 diagnosis overall, with a predominance of men among
250	those on a mechanical ventilator (57%).
251	
252	Patients with COVID-19 were more likely to have black or African American race (25%) than
253	patients with influenza (18%) or viral pneumonia (15%). Among hospitalized/ED patients, the
254	proportion of patients with black or African American race was similar for COVID-19 and
255	influenza patients (29% and 28%) but higher than for patients with viral pneumonia (18%).
256	However, COVID-19 (16%) and influenza (15%) patients were more commonly categorized as
257	having "missing" or "other" race than those with viral pneumonia (8%).

Table 1: Characteristics of patients diagnosed with COVID-19, viral pneumonia and influenza, January 1 – May 18, 2020, 36 PCORnet Data Contributing Institutions

	COVID Diagnosis Any Care Setting 24,516		Diagnosis Any in an Ambulatory					COVID Diagnosis in an Inpatient or Emergency Department Setting AND Mechanical Ventilation		Viral Pneumonia Diagnosis AND NO COVID Diagnosis in an Inpatient or Emergency Department Setting		Influenza Diagnosis and No COVID Diagnosis in an Inpatient or Emergency Department Setting	
			9,305		10,351		921		42,100		66,558		
	N	%	N	%	N	%	N	%	Ν	%	Ν	%	
Age	Age												
0-<2	1,087	4%	196	2%	770	7%	60	7%	1,968	5%	9,018	14%	
2-<10	976	4%	309	3%	544	5%	44	5%	4,742	11%	24,207	36%	
10-<20	1,105	5%	494	5%	457	4%	33	4%	2,003	5%	8,647	13%	
20-<45	8,890	36%	3,960	43%	2,864	28%	125	14%	6,650	16%	13,173	20%	
45-<65	7,918	32%	3,101	33%	3,249	31%	309	34%	10,966	26%	7,063	11%	

65-<75	2,530	10%	778	8%	1,287	12%	197	21%	7,088	17%	2,517	4%
75-<85	1,329	5%	313	3%	764	7%	109	12%	5,544	13%	1,362	2%
85+	644	3%	107	1%	410	4%	22	2%	3,103	7%	540	1%
Sex												
Female	13,447	55%	5,255	56%	5,231	51%	381	41%	20,828	49%	34,126	51%
Male	10,965	45%	3,970	43%	5,108	49%	525	57%	21,219	50%	32,318	49%
Other <sup>1</sup>	104	0%	80	1%	12	0%	0	0%	52	0%	114	0%
Race	Race											
Native Hawaiian or Other Pacific Islander	133	1%	55	1%	70	1%	0	0%	192	0%	438	1%
American Indian or Alaska Native	110	0%	35	0%	62	1%	0	0%	176	0%	215	0%
Asian	668	3%	234	3%	315	3%	27	3%	829	2%	2,061	3%
Black or African American	6,148	25%	1,729	19%	3,002	29%	236	26%	7,690	18%	18,911	28%

White	12,523	51%	5,053	54%	5,159	50%	492	53%	29,174	69%	33,465	50%
Multiple Race	291	1%	104	1%	107	1%	0	0%	506	1%	1,747	3%
Other <sup>1</sup> /Missing	4,621	19%	2,071	22%	1,607	16%	119	13%	3,488	8%	9,706	15%
Month <sup>2</sup>	Month <sup>2</sup>											
January 2020	1,193	5%	153	2%	937	9%	90	10%	13,490	32%	26,717	40%
February 2020	828	3%	105	1%	664	6%	65	7%	11,553	27%	28,087	42%
March 2020	6,240	25%	1,449	16%	2,925	28%	358	39%	10,937	26%	11,542	17%
April 2020	13,070	53%	5,796	62%	4,735	46%	365	40%	5,363	13%	179	0%
May 2020	3,162	13%	1,783	19%	1,082	10%	21	2%	757	2%	19	0%

\*Columns may not add to the total N of patients due to some missing data that is not categorized separately as missing. Further, small cell sizes with <11 patients are suppressed, leading to some differences in totals and percent values.

<sup>1</sup> "Other" includes all remaining PCORnet CDM values not specified by this request.

<sup>2</sup> For by year-month counts, the reported period represents the month and year in which the health event of interest first occurred within the query period. Data for May 2020 only includes information through the middle of the; the query to acquire this data was circulated on May  $7^{th}$  and ended on May  $18^{th}$ .

259

260

260	
261	Comorbidities were common among all infections. Among COVID-19 patients, hypertension
262	was the most common comorbidity (32% for all patients) followed by arrhythmias (20%),
263	pulmonary disease (19%), type 2 diabetes (17%), anemia (14%), and asthma (12%). These
264	diagnoses were more common among COVID-19 patients being treated in the inpatient or
265	emergency department setting (Fig 2A). Compared to patients with viral pneumonia treated in
266	the inpatient/ED setting, COVID-19 patients in this same care setting had fewer comorbidities
267	(arrhythmia: 33% vs. 45%; pulmonary disease: 24% vs. 43%; congestive heart failure: 13% vs.
268	26%; coronary artery disease: 13% vs. 24%); patients with influenza in the inpatient/ED setting
269	had much lower prevalence of comorbidities, likely, in large part, because patients were younger
270	(arrhythmia: 15%; pulmonary disease: 21%; congestive heart failure 4%; coronary artery
271	disease: 4%) (Fig 2B). Asthma rates were similar across all three disease groups (14% to 19%).
272	Obesity was more common among COVID-19 patients <65 years old hospitalized or in ED (40%
273	among 20-44-year-olds; 45% among 45-64-year-olds; 36% among 65-74-year-olds) compared to
274	patients with viral pneumonia (32%, 38%, 36%, respectively) and influenza (26%, 37%, 35%,
275	respectively) (S3 Table).

276

# Fig 2. Comorbidities for Patients with COVID-19 Across Care Settings and Compared to Patients with Viral Pneumonia and Influenza in the Inpatient/Emergency Department Setting.

- These figures show prevalence of various important comorbidities for COVID-19 infections across care settings (A), including all patients and those diagnosed in ambulatory settings, inpatient/emergency department, or using mechanical ventilation. In (B), we compared patients with COVID-19, viral pneumonia, and influenza among those who were hospitalized or in the emergency department. Care settings are not mutually exclusive. Patients could be in all care settings, such as if a patient receives a COVID-19 diagnosis in each of the ambulatory and inpatient/emergency department settings.
- 287

288	Among patients hospitalized or in the ED, critical care procedure/billing codes appeared for 13%
289	of patients diagnosed with COVID-19 compared to 16% of those with viral pneumonia and 2%
290	with influenza. Of treatments assessed, corticosteroids and hydroxychloroquine were used
291	commonly for COVID-19 patients in the inpatient/emergency department setting (12% and 15%,
292	respectively); 10% of patients in this setting used the combination of hydroxychloroquine and
293	azithromycin (Table 2). Chloroquine use was very infrequent. Tocilizumab was used most often
294	among patients on mechanical ventilators (11%) as was hydroxychloroquine (33%), with rare
295	use of other anti-interleukin-6 agents. Hydroxychloroquine or the combination of it with
296	azithromycin was used for 1% or fewer of the patients hospitalized or in the ED with viral
297	pneumonia or influenza.

298

	COVID Any		COVID Ambulatory		COVID Emergency Department /Inpatient		COVID Ventilator		Emergenc	neumonia y Department patient	Influenza Emergency Department /Inpatient	
Hydroxychloroquine	1,915	8%	257	3%	1,514	15%	302	33%	618	1%	94	0%
Hydroxychloroquine +Azithromycin*	1,250	5%	125	1%	993	10%	233	25%	326	1%	26	0%
Corticosteroids	2,270	9%	354	4%	1,202	12%	198	21%	10,259	24%	5,074	8%
Tocilizumab	346	1%	12	0.001%	284	3%	101	11%	16	0.0004%	0	0%

\*Not mutually exclusive; patients on hydroxychloroquine and azithromycin are also counted in the hydroxychloroquine row.

#### 300 Discussion

301 In this article, we describe one of the largest cohorts reported to date, using information on 24,516 patients diagnosed with COVID-19 across the U.S. Unlike most other studies, we 302 303 compare patients across care settings and describe patients diagnosed with viral pneumonia (N=79,639) and influenza (N=163,984) during the COVID-19 pandemic. Comorbidities were 304 305 common among patients diagnosed with COVID-19, especially those cared for in the emergency 306 department and inpatient setting; prevalence of comorbidities was more higher among patients diagnosed with viral pneumonia and lower among those with influenza. Treatments, such as 307 308 hydroxychloroquine were commonly used among patients diagnosed with COVID-19. Among 309 patients on mechanical ventilators, 1/3 of patients were using hydroxychloroquine and <sup>1</sup>/<sub>4</sub> using it in combination azithromycin. Obtaining real-world, comprehensive information on a diverse, 310 national population of patients with COVID-19 is critical to help guide policymakers as well as 311 clinical and public health leaders regarding planning for future COVID-19 response. These 312 313 results provide information on the high burden of chronic disease among COVID-19 patients, 314 compared to those with other similar infections, especially among patients requiring ED visits or hospitalization. The depth and breadth of the PCORnet data infrastructure will facilitate wide-315 ranging observational and interventional research, with strong generalizability. 316

317

Several prior studies have assembled and characterized cohorts of COVID-19 patients mostly using lab test results and extracts from medical records or case reports. These studies originated in China and have emerged from various hotspots across the world as the pandemic has spread. One of the first reports included data on 1099 hospitalized patients across 30 Chinese provinces, representing 14% of patients who had been hospitalized in 552 hospitals at the time. In the

323 cohort, mean age was 47 years, and 24% of patients had an underlying health condition, of which 324 hypertension (15%) and diabetes (7%) were the most common. Patients with more severe disease were more likely to have an underlying health condition (39%) (22). Underscoring the need for 325 326 large cohorts over diverse geographic regions, subsequent reports from China have found wide variation in characteristics of patients infected with COVID-19 (23). For example, in one study 327 328 of hospitalized patients across China, patients in Hubei province, the epicenter of the outbreak, 329 were older and had a higher burden of comorbidities (33%) compared to patients outside of Hubei (20%) (24). Diabetes rates were 12% vs. 5%, and hypertension was 24% vs. 12%. 330 331 Studies in the United States began with single case reports or case series in Washington state (1, 332 25) and have grown to include large collections of patients, typically within single healthcare 333 systems or from case reports to public health authorities. In the Northwell healthcare system in 334 New York State, investigators captured data on 5700 inpatients, mostly hospitalized in March 335 336 2020, from their EHR data warehouse. Median age of patients was 63 years, 23% were black or 337 African American, and 40% were female; 57% had hypertension, 42% obesity (severe obesity 19%), and 34% diabetes. Among patients, 14% received treatment in an intensive care unit, and 338 12% had received mechanical ventilation (26). 339 340

Research and surveillance networks have begun reporting on COVID-19. The Observational
Health Data Sciences and Informatics (OHDSI) group, which manages the Observational
Medical Outcomes Partnership (OMOP) Common Data Model, has published data characterizing
patients with COVID-19 compared to influenza. OHDSI uses a similar process to PCORnet, with
queries that do not require sharing of patient-level data (27). OHDSI network partners

346	contributed information on COVID-19 patients hospitalized in South Korea (captured from a
347	national health insurance claims database) and in three US healthcare systems. Of 6806 patients
348	(75% of them from South Korea) identified based on positive SARS-CoV-2 lab tests, the most
349	common chronic conditions were hypertension (22% to 70% across sites), anemia (14% to 30%),
350	and diabetes (18% to 43%), with the highest burden of chronic disease by far among the 577
351	patients cared for in Department of Veterans Affairs facilities. In contrast to our study, patients
352	in this OHDSI cohort hospitalized with influenza from 2014 to 2019 were older and had a higher
353	burden of comorbidities than those with COVID-19.
354	
355	Data on children with COVID-19 are sparse. Among 2572 children under 18 years reported to
356	the Centers for Disease Control and Prevention, 345 children had information on underlying
357	health conditions; 23% of these children had documentation of at least one, most of which were
358	asthma or cardiovascular disease (8). Our study has information available for 3168 children
359	under 20 years of age, 56% of whom were hospitalized; in future iterations of our work, we will
360	have the capacity to report separately on the specific comorbidity burden among children
361	diagnosed with COVID-19 compared to other viral illnesses.
362	
363	COVID-19 surveillance in PCORnet provides several unique opportunities. The network

infrastructure and large samples can allow for creation of research-ready cohorts and in-depth assessment of patients, based on demographic or clinical characteristics. Analyses can be done in a distributed fashion without sharing of patient-level data, including predictive modeling, and aggregation across diverse sites can increase generalizability. Large sample sizes with granular clinical information will be increasingly important to capture information on patient subgroups,

369 defined by demographics or less common presentations or outcomes of COVID-19, such as 370 emerging reports of neurologic complications or rare complications in children (28). PCORnet 371 will also facilitate observational research and clinical trials on various treatments; even in this 372 early phase of data capture, we have identified thousands of patients receiving treatments, such as hydroxychloroquine. By continuously updating and refining COVID-19 data, PCORnet will 373 374 allow for contemporaneous comparisons to patients diagnosed with other similar illnesses, such 375 as viral pneumonia and influenza in this study as well as concurrent trials; soon, we will compare 376 patients who have "positive" and "negative" SARS-CoV-2 tests. The investment in changing the 377 processes for data management – moving to a weekly update for patients with respiratory illness from a quarterly update – set up the network to make ongoing contributions to the investigation 378 of COVID-19. 379

380

In contrast, PCORnet does not allow for representative estimates of overall COVID-19 cases 381 382 across the U.S. Because PCORnet has a fixed number of institutions and is not designed to be 383 representative of the U.S. population, the prevalence of cases across states in PCORnet is not equivalent to the actual state prevalence of COVID-19 patients. Also, in this early stage of 384 385 exploring COVID-19 in PCORnet, the case definition depended on diagnostic codes. Patients actively diagnosed with COVID-19, which in our case included codes for other coronaviruses, 386 likely differ from those who test positive for SARS-CoV-2. Diagnostic codes are less sensitive 387 388 than lab test results though perhaps more specific, considering that many patients with positive 389 lab tests are asymptomatic and do not have the syndrome of COVID-19. Sensitivity of diagnostic codes for COVID-19 was likely much lower for patients who were diagnosed before an ICD-10-390 391 CM code was available for COVID-19 (April 1, 2020) (29). Prior to that time, the Centers for

Disease Control and Prevention provide interim guidance on use of existing coronavirus codes
that were not specific to COVID-19 (30). The presence of the U07.1 code already has led to
more case identification, with most of the cases identified in April and May using this code.
Because of the uncertainty of diagnostic codes in the early phase of the pandemic, some patients
with other coronavirus infections would have been misclassified as having COVID-19 in our
study.

398

399 *Limitations* 

400 Several limitations are inherent to working with structured healthcare data. First, electronic health records may not have complete data on some patients, especially patients diagnosed in 401 virtual visits or who were diagnosed and treated entirely outside of a PCORnet health system, 402 including in skilled nursing facilities or nursing homes. In such cases, the PCORnet Common 403 Data Model may not have any information about a COVID-19 infection or inadequate 404 information on chronic diseases and medication use. We separately captured information on 405 406 patients who were seen in the healthcare system prior to their hospitalization or emergency department visit for COVID-19; among these patients, prevalence of comorbidities was slightly 407 408 higher when compared to all patients seen in the emergency department or hospitalized. Missing 409 data can also be an issue for variables such as race. Some medications being used in research protocols also were likely missing because they are not captured in routine medication 410 411 administration tables. Second, because the research network was set up to accommodate 412 quarterly refreshes of clinical data, we quickly changed protocols to allow for weekly updates. The standard quarterly data refreshes undergo detailed curation to ensure that data are compliant 413 414 with standards of the Common Data Model, and such efforts are not possible with weekly

415 refreshes. Erroneous records may exist that will only be identified later through data curation. 416 The PCORnet Coordinating Center will soon implement regular data curation for the COVID-19 417 Common Data Model. Third, during these initial queries, we categorized weight status by age 418 group, but we did not fully separate children or adults for the determination of comorbidities and treatments; this led to lower prevalence of comorbidities for patients with influenza. Future 419 420 queries will separate categorize adults and children. Fourth, overlap likely existed between disease groups. Patients diagnosed with viral pneumonia or influenza might have had COVID-19 421 but either did not receive a test or were misclassified based on diagnostic coding. Only 12% of 422 423 patients with viral pneumonia and 1% with influenza had a recorded SARS-CoV-2 test, compared to 68% for patients with COVID-19. These SARS-CoV-2 test results are likely an 424 undercount; some sites have not yet fully loaded their test results into PCORnet data models, and 425 426 others might not have information on tests done outside of the health system, such as in drivethru testing facilities or private labs. 427

428

#### 429 *Conclusion and Next Steps in Development*

PCORnet has captured information on one of the largest cohorts to date of patients diagnosed with COVID-19 and other respiratory illnesses. Patients diagnosed with COVID-19 have a high burden of chronic disease, and treatments are common. We have updated data infrastructure to allow for weekly updates and queries of patients, with COVID-19 case definitions initially based on diagnostic codes. We will soon identify and characterize cohorts based on lab results, along with additional improvements such as identifying patients based on institutional registries, improved definitions of care settings, and detailed stratifications by patient characteristics.

### 438 Collaborative Authors: *PCORnet*<sup>®</sup> Network Partners

439 H. Timothy Bunnell, PhD, Nemours Children's Health System; Ryan Carnahan, PharmD, MS, The University of Iowa College of Public Health, Department of Epidemiology; Alanna M. 440 441 Chamberlain, PhD, MPH, Department of Health Sciences Research, Mayo Clinic; Dimitri A Christakis, MD MPH, Center for Child Health, Behavior & Development, Seattle Childrens 442 Research Institute, University of Washington; Lindsay G. Cowell, MS, PHD, UT Southwestern 443 444 Medical Center; Janis L. Curtis, MSPH, MA, Duke University School of Medicine; Julia A. Fearrington, Harvard Pilgrim Health Care Institute; Soledad A. Fernandez, PhD, The Ohio State 445 University; David A Hanauer, MD, MS, University of Michigan; Kristin Herman, Tallahassee 446 Memorial Healthcare, Inc; Rachel Hess, MD, MS, Departments of Population Health Sciences 447 448 and Internal Medicine, University of Utah School of Medicine; Philip Giordano, MD, Orlando Health, Inc.; Wenke Hwang, PhD, Penn State University College of Medicine; Adam Lee, MBA, 449 NC TraCS Institute, University of North Carolina, Chapel Hill; Harold Lehmann MD 450 451 PhD, Health Science Informatics, Johns Hopkins School of Medicine; Simon Lin, MD, MBA, Nationwide Children's Hospital; Scott Mackey, DO, LCMC Health; Narayana Mazumber, MS, 452 Allina Health; James McClay, MD, MS, FACEP, FAMIA, University of Nebraska Medical 453 454 Center; Abu Saleh Mohammad Mosa, PhD, MS, FAMIA, University of Missouri School of Medicine; Jihad S. Obeid, MD, FAMIA, Biomedical Informatics Center, Department of Public 455 456 Health Sciences, Medical University of South Carolina; Brian Ostasiewski, B.S., Wake Forest 457 School of Medicine; Nathan M. Pajor, MD, MS, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, and Departments of Pediatrics, University of Cincinnati; 458 Aruradha Paranjape, MD, MPH, Lewis Katz School of Medicine at Temple University; Suchitra 459 Rao, MBBS, MSCS, University of Colorado School of Medicine and Children's Hospital 460 Colorado; Pedro Rivera, OCHIN; Patricia S. Robinson, PhD, APRN, NE-BC, AdventHealth; 461 Marc Roseman, Ann & Robert H. Lurie Children's Hospital of Chicago; Steffani Roush, 462 Marshfield Clinic Health System: Jonathan C. Silverstein, MD, MS, Department of Biomedical 463 Informatics, University of Pittsburgh School of Medicine; Alexander Stoddard, MS, CTSI, 464 Medical College of Wisconsin; William E. Trick, Center for Health Equity & Innovation, Cook 465 County Health; Katherine J Worley, MLIS, Vanderbilt University Medical Center 466 467

#### 468 Acknowledgement

469 The Clinical Research Networks, Health Plan Research Networks, and Coordinating Center

- 470 reported in this publication are Network Partners in PCORnet, the National Patient-Centered
- 471 Clinical Research Network. PCORnet has been developed with funding from the Patient-
- 472 Centered Outcomes Research Institute (PCORI). The Network Partners' participation in
- 473 PCORnet is funded through the following PCORI Awards: Coordinating Center (PCORI-CC2-
- 474 Duke-2016); ADVANCE (RI-CRN-2020-001); CaPriCORN (RI-CRN-2020-002); GPC (RI-
- 475 CRN-2020-003); HealthCore (HP-1510-32545); Insight (RI-CRN-2020-004); OneFlorida (RI-
- 476 CRN-2020-005); PaTH (RI-CRN-2020-006); PEDSnet (RI-CRN-2020-007); PRACnet (HP-
- 477 1511-32713); REACHnet (RI-CRN-2020-008); and, STAR (RI-CRN-2020-009). Authors report
- 478 no competing interests associated with this publication.
- 479

Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19

in Critically III Patients in the Seattle Region - Case Series. The New England journal of

#### 480 References

medicine. 2020.

1.

2.

481 482

483

484 485

Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. 486 Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morbidity and 487 488 mortality weekly report. 2020;69(15):458-64. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical 489 3. Characteristics of Covid-19 in New York City. The New England journal of medicine. 2020. 490 491 4. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized Adults With 492 COVID-19 in an Integrated Health Care System in California. Jama. 2020. Nikpouraghdam M, Jalali Farahani A, Alishiri G, Hevdari S, Ebrahimnia M, Samadinia 493 5. 494 H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. Journal of clinical virology : the official publication of the Pan 495 496 American Society for Clinical Virology. 2020;127:104378. 497 Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United 6. States, February 12-March 16, 2020. MMWR Morbidity and mortality weekly report. 498 499 2020;69(12):343-6. 500 7. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. 501 502 MMWR Morbidity and mortality weekly report. 2020;69(13):382-6. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. 503 8. MMWR Morbidity and mortality weekly report. 2020;69(14):422-6. 504 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in 505 9. real time. The Lancet Infectious diseases. 2020;20(5):533-4. 506 507 10. DeJong C, Wachter RM. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm. JAMA internal medicine. 2020. 508 509 Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT 11. 510 Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus 511 Disease 2019 (COVID-19). JAMA cardiology. 2020. 512 513 12. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients 514 515 Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: 516 A Randomized Clinical Trial. JAMA network open. 2020;3(4):e208857. 517 Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. 13. Journal of the American Medical Informatics Association : JAMIA. 2014;21(4):576-7. 518 519 Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, 14. a national patient-centered clinical research network. Journal of the American Medical 520 Informatics Association : JAMIA. 2014;21(4):578-82. 521

- 522 15. The National Patient-Centered Clinical Research Network (PCORnet), Data-Driven
- Common Model. 2020 [Available from: https://pcornet.org/data-driven-common-model/. 523

- 16. Qualls LG, Phillips TA, Hammill BG, Topping J, Louzao DM, Brown JS, et al.
- Evaluating Foundational Data Quality in the National Patient-Centered Clinical Research
  Network (PCORnet(R)). EGEMS (Washington, DC). 2018;6(1):3.
- 527 17. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-
- 528 CM) 2020 [Available from: <u>https://www.cdc.gov/nchs/icd/icd10cm.htm</u>.
- 529 18. LOINC prerelease terms 2020 [Available from: <u>https://loinc.org/prerelease/</u>.
- 19. RxMix: creating applications from NLM Drug APIs 2020 [Available from:
- 531 <u>https://mor.nlm.nih.gov/RxMix/</u>.
- 532 20. First Databank. Functional classification system. 2020 [Available from:
- 533 <u>http://www.fdbhealth.com/</u>.
- 534 21. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al.
  535 CDC growth charts: United States. Advance Data. 2000(314):1-27.
- 536 22. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
- 537 Coronavirus Disease 2019 in China. The New England journal of medicine. 2020;382(18):1708-538 20.
- 539 23. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of
- coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. TheJournal of infection. 2020.
- 542 24. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics
- and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside
  Hubei (non-epicenter): A Nationwide Analysis of China. The European respiratory journal.
- 545 2020.
- 546 25. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of
  547 2019 Novel Coronavirus in the United States. The New England journal of medicine.
- 548 2020;382(10):929-36.
- 26. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
- 550 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized
- 551 With COVID-19 in the New York City Area. Jama. 2020.
- 552 27. Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahao MTF, et al. An international 553 characterisation of patients hospitalised with COVID-19 and a comparison with those previously 554 hospitalised with influenza. Pre-print on medRxiv. 2020 [Available from:
- 555 https://www.medrxiv.org/content/10.1101/2020.04.22.20074336v1.full.pdf.
- 556 28. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic 557 Features in Severe SARS-CoV-2 Infection. The New England journal of medicine. 2020.
- Features in Severe SARS-COV-2 infection. The New Eligiand journal of medicine. 2020.
- 558 29. ICD-10-CM official coding and reporting guidelines April 1, 2020 through September
- 559 30, 2020 [Available from: <u>https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf</u>.
- 30. ICD-10-CM official coding guidelines supplement coding encounters related to
- 561 COVID-19 coronavirus outbreak 2020 [Available from: <u>https://www.cdc.gov/nchs/data/icd/ICD-</u>
- 562 <u>10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf</u>.

A)





